Email Alert RSS
Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2023  >  14(1): 190-195
LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189
Citation: LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189
shu

Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

doi: 10.12290/xhyxzz.2022-0189
  • 1.

    The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

  • 2.

    Department of Obstetrics and Gynecology, Gansu Provincial Key Laboratory of Gynecological Oncology, First Hospital of Lanzhou University, Lanzhou 730000, China

Funds:

Science and Technology Project of Gansu Province 21JR7RA378

More Information
  • Corresponding author: XU Feixue, E-mail: xfx.sxq@163.com
  • Received Date: 2022-04-07
  • Accepted Date: 2022-04-15
    • Available Online: 2022-05-31
  • Publish Date: 2023-01-30
    Abstract
  • Lynch syndrome (LS), an autosomal dominant genetic disorder caused by mismatch repair gene defects, is characterized by the susceptibility to multi-system malignancies. LS associated endometrial cancer (LS-EC) is the most common extraintestinal sentinel cancer of LS. In the era of precision medicine, early screening of LS-EC is of great significance to preventing the occurrence of other LS related malignant tumors. This paper reviews the research progress on screening methods and prevention of LS-EC, in order to provide reference for precise diagnosis and prevention of LS-related tumors.
    • FullText(HTML)
  • loading
    • References(30)
  • [1] Dörk T, Hillemanns P, Tempfer C, et al. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management[J]. Cancers (Basel), 2020, 12: 2407. doi:  10.3390/cancers12092407
    [2] Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150: 7-17. doi:  10.1002/ijc.33763
    [3] Pastor DM, Schlom J. Immunology of Lynch Syndrome[J]. Curr Oncol Rep, 2021, 23: 96. doi:  10.1007/s11912-021-01085-z
    [4] Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology, 2010, 56: 167-179. doi:  10.1111/j.1365-2559.2009.03392.x
    [5] Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study[J]. Lancet Oncol, 2011, 12: 49-55. doi:  10.1016/S1470-2045(10)70265-5
    [6] Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation[J]. J Med Genet, 2018, 55: 240-248. doi:  10.1136/jmedgenet-2017-104744
    [7] Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22: 15-25. doi:  10.1038/s41436-019-0596-9
    [8] Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies[J]. JAMA Oncol, 2017, 3: 1702-1706. doi:  10.1001/jamaoncol.2017.0619
    [9] Staff S, Aaltonen M, Huhtala H, et al. Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study[J]. Br J Cancer, 2016, 115: 375-381. doi:  10.1038/bjc.2016.193
    [10] Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma[J]. Cancer, 2006, 106: 87-94. doi:  10.1002/cncr.21560
    [11] Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study[J]. Int J Gynecol Cancer, 2017, 27: 953-960. doi:  10.1097/IGC.0000000000000985
    [12] Ramchander NC, Ryan NAJ, Walker TDJ, et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol, 2020, 10: 3023. doi:  10.3389/fimmu.2019.03023
    [13] Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes[J]. Int J Gynecol Cancer, 2020, 30: 56-61. doi:  10.1136/ijgc-2019-000824
    [14] Carr C, Son J, Yao M, et al. Clinicopathologic characteri-stics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol, 2020, 159: 712-720. doi:  10.1016/j.ygyno.2020.09.039
    [15] 杨子慧, 刘新宇, 杨曦, 等. 林奇综合征患者子宫内膜癌及卵巢癌的筛查与预防[J]. 国际妇产科学杂志, 2021, 48: 453-456. Yang ZH, Liu XY, Yang X, et al. Screening and prevention of endometrial carcinoma and ovarian cancer in patients with Lynch syndrome[J]. Guoji Fuchanke Zazhi, 2021, 48: 453-456. doi:  10.12280/gjfckx.20201174
    [16] Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1[J]. Gastroenterology, 2005, 129: 537-549.
    [17] Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors[J]. Cancers (Basel), 2021, 13: 467. doi:  10.3390/cancers13030467
    [18] Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression[J]. Cancer Res, 1997, 57: 4749-4756.
    [19] Houlleberghs H, Dekker M, Lusseveld J, et al. Three-step site-directed mutagenesis screen identifies pathogenic MLH1 variants associated with Lynch syndrome[J]. J Med Genet, 2020, 57: 308-315. doi:  10.1136/jmedgenet-2019-106520
    [20] Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel), 2021, 13: 406. doi:  10.3390/cancers13030406
    [21] Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383: 2053-2064. doi:  10.1056/NEJMra1514010
    [22] Van den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer, 2021, 31: 594-604. doi:  10.1136/ijgc-2020-001822
    [23] Gompel A. Progesterone and endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 69: 95-107. doi:  10.1016/j.bpobgyn.2020.05.003
    [24] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372: 2509-2520. doi:  10.1056/NEJMoa1500596
    [25] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsa-tellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase Ⅱ KEYNOTE-158 Study[J]. J Clin Oncol, 2020, 38: 1-10.
    [26] Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial[J]. Lancet, 2020, 395: 1855-1863. doi:  10.1016/S0140-6736(20)30366-4
    [27] Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospec-tive Lynch Syndrome Database report[J]. Eur J Cancer, 2021, 148: 124-133. doi:  10.1016/j.ejca.2021.02.022
    [28] Crosbie EJ, Ryan NAJ, Arends MJ, et al. Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med, 2019, 21: 2390-2400. doi:  10.1038/s41436-019-0489-y
    [29] Roudko V, Cimen Bozkus C, Greenbaum B, et al. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines[J]. Front Immunol, 2021, 12: 757804. doi:  10.3389/fimmu.2021.757804
    [30] Bayó C, Jung G, Español-Rego M, et al. Vaccines for Non-Viral Cancer Prevention[J]. Int J Mol Sci, 2021, 22: 10900. doi:  10.3390/ijms222010900
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (189) PDF downloads(47) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return